Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipelinenews2022-05-11T11:29:17+00:00May 11th, 2022|FierceBiotech|
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reelingnews2022-05-11T07:33:53+00:00May 11th, 2022|FierceBiotech|
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideasnews2022-05-10T22:26:19+00:00May 10th, 2022|FierceBiotech|
Rallybio wades into Sanofi storeroom for $3M rare disease dealnews2022-05-10T16:33:14+00:00May 10th, 2022|FierceBiotech|
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new namenews2022-05-10T14:26:28+00:00May 10th, 2022|FierceBiotech|
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spraynews2022-05-10T13:25:01+00:00May 10th, 2022|FierceBiotech|
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 yearsnews2022-05-10T12:38:36+00:00May 10th, 2022|FierceBiotech|
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidatesnews2022-05-10T12:23:23+00:00May 10th, 2022|FierceBiotech|
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indicationnews2022-05-10T10:26:01+00:00May 10th, 2022|FierceBiotech|
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’news2022-05-09T19:54:53+00:00May 9th, 2022|FierceBiotech|
